Dr Alejandro Forner, Spain
Dr Alejandro Forner achieved his medical degree at the University “Miguel Hernández”, Alicante, Spain, in June 1999, obtaining the Extraordinary Licensure Award for the best medical school academic expedient. He obtained the Board certification in Gastroenterology and Hepatology in the Liver and Gastroenterology Unit, Hospital Clinic, Barcelona (2001-2005) and since 2005, he works in the Barcelona Clinic Liver Cancer Group (BCLC) group, Liver Unit, Hospital Clinic Barcelona.
Prof. Peter Galle, Germany
Prof. Peter Galle (MD, PhD) majored in internal medicine at the Universities of Berlin and Marburg/Germany, Hammersmith Hospital, London/UK and University of Texas/USA and received his M.D. degree from Marburg University and Ph.D. degree from Heidelberg University.
He is member of several national and international societies such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), served as Co-editor for the Journal of Hepatology and is on the Editorial Boards of several other Journals. He served as congress president of the German Society for Digestive Diseases (DGVS) in 2014. He was member of the Executive Board and President of the International Liver Cancer Association (ILCA).
His research has focused on elucidating important aspects of apoptotic cell death in the liver, immune escape of tumour cells and on clinical and molecular aspects of hepatocellular carcinoma. He was awarded several prizes, amongst others the prestigious Tannhauser award, the highest prize of the German Society for Digestive Diseases. He has published more than 500 peer-reviewed papers.
Prof. Jessica Zucman-Rossi, France
Prof. Jessica Zucman-Rossi and her team develop basic genomic approaches based on human tumors analyses to identify new mechanisms of tumorigenesis in the liver and to transfer this knowledge into biomarkers and therapeutic targets that could be introduced in clinical care.
The team also aims to translate genomic findings into the clinics to improve surveillance, diagnosis, prognosis, treatment and follow-up of the patients with benign and malignant tumors.